Chronic Spontaneous Urticaria Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2023-32) - DelveInsight | Amgen, Novartis, Allakos, Sanofi, Celltrion, Servier, Celldex

The Chronic Spontaneous Urticaria Market size in the 7MM was approximately USD 2,084.6 million in 2022 and is projected to increase during the forecast period (2023-2032). As per DelveInsight, the Chronic Spontaneous Urticaria Market is anticipated to evolve immensely in the coming years owing to the rise in the number of cases of Chronic Spontaneous Urticaria in the 7MM, extensive research and development activities of pharmaceutical companies, along with the expected launch of approved therapies in the market.

DelveInsight's "Chronic Spontaneous Urticaria Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Chronic Spontaneous Urticaria Market Size and Share in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The market report covers emerging drugs, treatment practices, market share of individual Chronic Spontaneous Urticaria therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Chronic Spontaneous Urticaria treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.

Chronic Spontaneous Urticaria: An Overview
Chronic spontaneous urticaria (CSU) or Chronic Idiopathic urticaria (CIU) is defined as persistent symptoms of urticaria for 6 weeks or more. It is a distressing skin condition that causes red, swollen, itchy and sometimes painful hives or "wheals" on the skin. It is being associated with autoimmunity in almost half of the cases, but the remaining cases still remain "idiopathic," and all are considered spontaneous. Therefore, the term chronic spontaneous urticaria (CSU) has been employed to indicate chronic urticaria that is endogenous and is independent of any external physical stimulus, which is conceptually helpful and does not imply knowing or not-knowing the cause.

The pathophysiology of CSU is not well-understood, but it is clear that derangement of both mast cell and basophil activation and degranulation remains central to the process. Of these, mast cells are most widely accepted as the primary effectors of chronic urticaria. While other cell types, including lymphocytes and poly-mononuclear cells (PMNs), have been observed within the inflammatory infiltrates of patients with CSU.

Approximately 40% of patients with CSU report accompanying episodes of angioedema, whereas 10% have angioedema as their primary manifestation. In most cases, it is a self-limiting disorder, persisting for 2-5 years in the majority of cases, although 20% of patients suffer for more than 5 years.

Chronic Spontaneous Urticaria Market Key Facts
• The market size of chronic spontaneous urticaria in the US will increase at a CAGR of 9.5% during the study period due to increasing awareness of the disease and the launch of the emerging therapy. The market size was approximately USD 1,104.4 million in 2022.
• The total market size of chronic spontaneous urticaria in EU4 and the UK was calculated to be approximately USD 600.8 million in 2022, which was nearly 28.8% of the total market revenue for the 7MM.
• In 2022, the total diagnosed prevalent cases of chronic urticaria were estimated to be approximately 4,154,234 cases in the 7MM. These cases are expected to decrease by 2032.
• Among the 7MM, the United States accounted for nearly 18.7% of the total diagnosed prevalent cases of chronic urticaria in 2022. These cases are expected to increase during the study period (2019-2032).
• In 2022, among the EU4 and the UK countries, Germany accounted for the highest diagnosed prevalent cases of chronic spontaneous urticaria, followed by France. While Spain accounted for the least diagnosed prevalent cases of chronic spontaneous urticaria. While Japan accounted for nearly 37.9% of the total diagnosed prevalent cases of chronic spontaneous urticaria in the 7MM.

Chronic Spontaneous Urticaria Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Chronic Spontaneous Urticaria therapies in the market. It also provides a detailed assessment of the Chronic Spontaneous Urticaria market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete detail of the market trend for each marketed Chronic Spontaneous Urticaria drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MOA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Discover How Chronic Spontaneous Urticaria Market will Grow by 2032:
https://www.delveinsight.com/report-store/chronic-spontaneous-urticaria-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Chronic Spontaneous Urticaria Epidemiology
The epidemiology section covers detailed insights into the historical, and current Chronic Spontaneous Urticaria patient pool and forecasted epidemiology trends for every seven major countries (7MM) from 2019 to 2032.

The Report Covers the Chronic Spontaneous Urticaria Epidemiology Segmented as-
• Total Prevalent cases of Chronic Spontaneous Urticaria in the 7MM [2019-2032]
• Gender-Specific cases of Chronic Spontaneous Urticaria in the 7MM [2019-2032]
• Age-specific cases of Chronic Spontaneous Urticaria in the 7MM [2019-2032]
• Total diagnosed and Treatable prevalent cases of CSU in the 7MM [2019-2032]

Get Key Insights Into the Evolving Chronic Spontaneous Urticaria Epidemiology Trends:
https://www.delveinsight.com/report-store/chronic-spontaneous-urticaria-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Chronic Spontaneous Urticaria Drugs Uptake and Pipeline Development Activities
The drugs' uptake section focuses on the rate of uptake of the potential drugs recently launched in the Chronic Spontaneous Urticaria market or expected to be launched during the study period. The analysis covers the market share by Chronic Spontaneous Urticaria drugs, patient uptake by therapies, and sales of each drug.

The report's drugs uptake section helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It allows the comparison of the drugs based on market share and size, which again will be helpful in investigating factors important in understanding the market dynamics and in making financial and regulatory decisions.

The report also covers the Chronic Spontaneous Urticaria Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Explore More About Ongoing Pipeline Development Activities:
https://www.delveinsight.com/sample-request/chronic-spontaneous-urticaria-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Chronic Spontaneous Urticaria Therapeutics Assessment
Several major pharma and biotech companies are developing therapies for Chronic Spontaneous Urticaria. Currently, Sanofi is leading the therapeutics market with its Chronic Spontaneous Urticaria drug candidates in the most advanced stage of clinical development.

The Leading Players in the Chronic Spontaneous Urticaria Therapeutics Market Include:
• United BioPharma
• Teva Pharmaceuticals Development, Inc.
• Amgen
• Novartis Pharmaceuticals
• Allakos Inc.
• Sanofi
• Celltrion
• Celldex Therapeutics
• MICROBIO GROUP.
• Escient Pharmaceuticals
• Jasper Therapeutics
• Glenmark Pharmaceuticals
• Taiho Pharmaceuticals
• ValenzaBio
• Carna Biosciences
• Servier
And Many Others

Chronic Spontaneous Urticaria Companies in the Market Include:
• Dupilumab: Sanofi
• Tezepelumab: Amgen
• Barzolvolimab: Celldex Therapeutics
• DUPIXENT (dupilumab): Sanofi/Regeneron
• Remibrutinib (LOU064): Novartis Pharmaceuticals
• Lirentelimab (AK002): Allakos/BioWa
• XOLAIR (omalizumab): Roche/Novartis
And Many More

Learn More About the Emerging Therapies & Key Companies in the Chronic Spontaneous Urticaria Therapeutics Market:
https://www.delveinsight.com/sample-request/chronic-spontaneous-urticaria-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Chronic Spontaneous Urticaria Competitive Intelligence Analysis
4. Chronic Spontaneous Urticaria Market Overview at a Glance
5. Chronic Spontaneous Urticaria Background and Overview
6. Chronic Spontaneous Urticaria Patient Journey
7. Chronic Spontaneous Urticaria Epidemiology and Patient Population
8. Chronic Spontaneous Urticaria Treatment Algorithm, Current Treatment, and Medical Practices
9. Chronic Spontaneous Urticaria Unmet Needs
10. Key Endpoints of Chronic Spontaneous Urticaria Treatment
11. Chronic Spontaneous Urticaria Marketed Products
12. Chronic Spontaneous Urticaria Emerging Therapies
13. Chronic Spontaneous Urticaria Seven Major Market Analysis
14. Attribute Analysis
15. Chronic Spontaneous Urticaria Market Outlook (7 major markets)
16. Chronic Spontaneous Urticaria Access and Reimbursement Overview
17. KOL Views on the Chronic Spontaneous Urticaria Market.
18. Chronic Spontaneous Urticaria Market Drivers
19. Chronic Spontaneous Urticaria Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.

Download the Sample PDF to Get Detailed Insights About the Report's Offerings:
https://www.delveinsight.com/sample-request/chronic-spontaneous-urticaria-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

-------------------------------------------- xx --------------------------------------------
Other Trending Healthcare Reports by DelveInsight -
• Radiofrequency Ablation Devices Market
https://www.delveinsight.com/report-store/radiofrequency-ablation-devices-market

• Smart Inhalers Market
https://www.delveinsight.com/report-store/smart-inhalers-market

• Persistent Depressive Disorder Market
https://www.delveinsight.com/report-store/persistent-depressive-disorder-market

• Dysthymia Market
https://www.delveinsight.com/report-store/dysthymia-market

• Nasopharyngeal Carcinoma Market
https://www.delveinsight.com/report-store/nasopharyngeal-carcinoma-market

• Spinal Fusion Devices Market
https://www.delveinsight.com/report-store/spinal-fusion-devices-market

• Stereotactic Surgery Devices Market
https://www.delveinsight.com/report-store/stereotactic-surgery-devices-market

• Structural Heart Devices Global Market
https://www.delveinsight.com/report-store/structural-heart-devices-market-market

• Intracardiac Echocardiography Devices Market
https://www.delveinsight.com/report-store/intracardiac-echocardiography-devices-market

• Cardiac Monitoring System Market
https://www.delveinsight.com/report-store/cardiac-monitoring-system-market

• Desmoplastic Small Round Cell Tumors (dsrcts) Market
https://www.delveinsight.com/report-store/desmoplastic-small-round-cell-tumors-market

• Artificial Cornea and Corneal Implant Market
https://www.delveinsight.com/report-store/artificial-cornea-and-corneal-implant-market

• Deep Brain Stimulation Devices Market
https://www.delveinsight.com/report-store/deep-brain-stimulation-devices-market

• Obesity Market
https://www.delveinsight.com/report-store/weight-loss-weight-management-obesity-market

Contact Info:
Shruti Thakur
Manager (Marketing & Branding)
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.